Table 1.
Clinical and Molecular Characteristics of Index Subjects
| Variables | n | % |
|---|---|---|
| Sex | ||
| Male | 233 | 46.5 |
| Female | 268 | 53.5 |
| Criteria | ||
| Bethesda | 378 | 75.4 |
| Amsterdam II | 123 | 24.6 |
| Tumor type | ||
| CRC | 463 | 92.4 |
| Endometrial | 24 | 4.8 |
| Others | 14 | 2.8 |
| MSI analysis | ||
| Positive | 102 | 20.4 |
| Negative | 371 | 74.0 |
| Not analyzed | 28 | 5.6 |
| IHQ analysis | ||
| Normal expression | 322 | 64.3 |
| MLH1 loss | 44 | 8.8 |
| MSH2 loss | 25 | 5.0 |
| Not analyzed | 110 | 21.9 |
| BRAF V600E mutation and/or MLH1 hypermethylation analysis* | ||
| Positive | 9 | 20.5 |
| Negative | 35 | 79.5 |
*
Analysis performed to Bethesda cases with loss of MLH1.